Novartis, the Swiss pharmaceutical giant, has seen a significant rise in its stock price, following an announced commitment to invest $23B into American manufacturing, despite tariff uncertainties. This move aligns Novartis with competitors Lilly and J&J, who have comparable US investments underway. The majority of the company's shares, approximately 53%, are currently held by individual investors, with institutions holding the remaining bulk. Analysts maintain a positive outlook on Novartis, noting its strength as a growth, momentum, and undervalued stock, despite minor dips due to tariff pressures. Furthermore, Novartis has weathered strong competition and demonstrates resilience with its hefty portfolio of branded drugs, earning it JP Morgan’s ‘Hold’ ranking. Bolstering its market position, is the approval of crucial treatments for rare kidney diseases. Recent Q4 earning reports surpassed expectations, with an upsurge in drug sales driving earnings. Despite a hiccup where Novartis’s stock dipped as a result of a $800million write-down, it has persistently leveraged key growth opportunities and built upon its solid foundation as a reliable dividend stock.
Novartis Stocks News Analytics from Thu, 18 Jul 2024 07:00:00 GMT to Fri, 11 Apr 2025 15:00:00 GMT -
Rating 7
- Innovation 4
- Information 8
- Rumor 1
